

Orthocell Appoints Executive Director Leslie Wise

- Orthocell has appointed experienced medical technology (medtech) executive, Leslie Wise, JD, as Executive Director
- Leslie has more than 20 years of specialist experience working in US reimbursement, life science, and medtech fields, and is ideally suited to support the next phase of Orthocell's development
- With a leading regenerative medicine portfolio and experienced senior advisory team, Orthocell is ideally positioned to drive its products into the US, EU and AUS markets

Perth, Australia; 10 June 2020: Regenerative medicine company Orthocell Limited (ASX:OCC, "Orthocell" or the "Company") is pleased to announce the appointment of Leslie Wise, JD, as Executive Director.

Orthocell Managing Director, Paul Anderson, said: "We are delighted to welcome Leslie to the Orthocell Board. Leslie has extensive experience in securing US market access and reimbursement for medical devices as well as serving in various senior management positions across large US medical device and pharmaceutical companies. Leslie's depth of knowledge and expertise is ideally suited to our product range and the next phase of growth for Orthocell."

Leslie Wise, JD, has extensive experience working for both medical device and pharmaceutical companies, including Bristol Myers-Squibb, Sanofi, Biomet Orthopedics and AngioDynamics. This has helped her to hone a valuable skillset in reimbursement, value evidence generation, clinical research strategy and frontline regulatory and payer experience. She has demonstrated experience in strategically integrating outcomes research, health policy analysis, payer insight, patient preference, along with stakeholder engagement – and has been instrumental in creating new standards for reimbursement in the medtech space.

Leslie regularly engages with leading experts in health technology assessment, health economics and is at the forefront of developing policies that support greater access for medical technologies. In recognition of her expertise, Leslie was re-appointed to the Medicare Evidence Development Coverage and Advisory Committee (MEDCAC) for 2018-2020. She also partnered with Advamed to facilitate the MedTech Value Summit inaugural event in Minneapolis in 2019.



Leslie Wise, JD, said: "I am very excited to be joining Orthocell at this pivotal stage in the company's development. Orthocell has one of the most advanced musculoskeletal regenerative medicine portfolios globally, and is poised to leverage its impressive clinical evidence to drive towards the US, EU and AUS markets. The timing could not be better for Orthocell as the broader Orthopaedic sector moves towards biologics and minimally invasive surgeries to deliver higher quality, more efficient and cost effective solutions."

For personal use only

Leslie is currently the Principal of EvidenceMatters, a Global Market Access consultancy. Before starting Evidence Matters, Leslie served as Vice President of Global Healthcare Economics and Healthcare Policy for AngioDynamics, a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and surgical oncology.

In 2019, Leslie was invited to serve on the board of directors of Sanarus, Inc a women's health technology company, focused on early stage breast cancer with a minimally invasive cryoablation technology. Leslie joined the board to provide guidance on re-tooling the reimbursement and regulatory strategy in response to feedback received from potential Strategic partners.

Orthocell has agreed that in addition to directors fees, the Company will issue Leslie Wise options under its Employee Securities Incentive Plan as follows; 2,000,000 options, vesting over 2 years, 1,000,000 upfront and 1,000,000 in 12 months from the initial issue date, with an exercise price at a 15% premium to the volume weighted average of the prices of Shares traded on ASX during the one week period up to and including the date of grant, expiring five years from date of issue. Shareholder approval will not be sought for the issue of options (or their exercise) as Leslie was not a director of Orthocell at the time of the negotiations and had no influence over the decision to issue the options.

Release authorised by:

Paul Anderson
Managing Director, Orthocell Ltd

For more information, please contact:

General & Investor enquiries

Paul Anderson
Orthocell Limited
Managing Director

P: +61 8 9360 2888

E: paulanderson@orthocell.com.au

Media enquiries

Haley Chartres
HACK Director

P: +61 423 139 163

E: haley@hck.digital

About Orthocell Limited

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of soft tissue injuries. Orthocell's portfolio of products include CelGro® platform technology, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications. Orthocell has received European regulatory approval (CE Mark) for CelGro® and is marketed within the European Union for a range of dental bone and soft tissue regeneration procedures. CelGro® is being readied for first approval in the US and AUS. The Company's other major focus is TGA-licensed cell therapies Autologous Tenocyte Implantation (Ortho-ATI®) and Autologous Chondrocyte Implantation (Ortho-ACI®), which aim to regenerate damaged tendon and cartilage tissue.

Orthocell is moving forward with clinical studies designed to assist in the US (FDA) approval process and has completed its pre-IND meetings with the FDA.

For more information on Orthocell, please visit www.orthocell.com.au or follow us on Twitter [@OrthocellLtd](https://twitter.com/OrthocellLtd) and LinkedIn www.linkedin.com/company/orthocell-ltd

Forward Looking Statement

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

For personal use only